The European Medicines Agency’s call came a day after the U.S. pharmaceutical giant said it was “voluntarily withdrawing” Oxbryta from global markets, after it found that the overall benefit of the drug no longer outweighed the risks
European Union watchdog puts sickle cell disease drug on ice
